Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Academic rigor, journalistic flair
Articles on mRNA vaccine
Displaying 1 - 20 of 45 articles
The COVID-19 mRNA vaccines put nanomedicine in the spotlight as a potential way to treat diseases like cancer and HIV. While the field isn’t there yet, better design could help fulfill its promise.
Existing coronavirus vaccines are not as effective against newer variants of the virus. Two vaccine experts explain how new vaccines currently in development will likely offer better protection.
Research suggests that too-frequent immunizations may lead to a phenomenon called “immune exhaustion.”
The COVID-19 pandemic has brought immunology terms that are typically relegated to textbooks into our everyday vernacular. These stories helped us make sense of the ever-evolving science.
Because COVID-19 is a relatively new virus, researchers still aren’t sure exactly how long vaccines and prior infections provide protection.
Myocarditis following COVID-19 vaccination is rare, and the risk is much smaller than the risks of cardiac injury linked to COVID-19 itself.
We’re reliant on overseas supply - and the many moving parts of delivery. Each of those parts require staff on the ground – and many workers in this system are likely being affected by Omicron.
Experts give us a science preview for 2022, plus what lies in store for global inequality. Listen to The Conversation Weekly podcast.
Some vaccine hesitancy is based on a fear of the nanoparticles used in mRNA vaccines. But humans have been interacting with nanoparticles for millennia, and we use nanotechnology-based devices every day.
A vaccine manufacturing facility will be built in Victoria to produce mRNA vaccines under an in-principle agreement between the federal government, the state government and global mRNA company Moderna
An infectious disease doctor explains the science behind COVID-19 vaccines at a level that children – and adults – of all ages can understand.
Each dose of Pfizer has a long and complex path involving mixing, storage at temperatures colder than the South Pole and specific protocols that must be followed before it becomes a jab.
With youth ages 12 and over eligible for COVID-19 vaccination — and as trials for younger children move ahead — parental hesitancy is emerging as the new challenge for COVID-19 vaccine programs.
This myth is still circulating online. Here’s why the chance of this happening is next to zero.
New Zealand’s approval of Pfizer’s COVID-19 vaccine for 12-15 year olds will bring the number of people eligible for the jab to 85% of the population, raising the chance of reaching collective immunity.
Various companies use different ingredients and different delivery systems in their COVID-19 vaccines. Researchers are investigating whether it’s better for individuals to mix what’s available.
Hundreds of thousands of Canadians got a shot of AstraZeneca’s COVID-19 vaccine for their first dose. They now have a choice for their second dose: AstraZeneca again, or Pfizer or Moderna mRNA vaccine?
A vaccine expert breaks down everything you need to know about Australia’s newest COVID-19 vaccine candidate.
Canadian public health organizations have run into a serious communication problem about the AstraZeneca vaccine. Crisis management and communication theories explain what’s gone wrong.
Top contributors
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Professor of Medicine, University of Virginia
-
Project Coordinator & Staff Scientist, Vanderbilt University Medical Center, Vanderbilt University
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Professor of Pathology, Microbiology and Immunology, University of South Carolina
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Early Career Research Leader, Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University
-
Bioengineer and Research Fellow, Monash University
-
Professor of Microbiology, School of Medicine, University of Washington
-
Pediatric Infectious Diseases Fellow, University of Pittsburgh Health Sciences
-
Australia's Chief Scientist, Office of the Chief Scientist
-
Leader, Science Communication Teaching Program, The University of Melbourne
-
Professorial Fellow, University of Canberra
-
Professor of Pharmaceutical Biology, Monash University
-
Associate professor, UNSW Sydney
